title: Correlation between location of transposed ovary and function in cervical cancer patients who underwent radical hysterectomy.
abstract: OBJECTIVE
  The study investigated the association between the location of transposed ovaries and posttreatment ovarian function in patients with early cervical cancer (IB1-IIA) who underwent radical hysterectomy and ovarian transposition with or without adjuvant therapies.
  
  
  METHODS
  Retrospective medical records were reviewed to enroll the patients with early cervical cancer who underwent ovarian transposition during radical hysterectomy at Samsung Medical Center between July 1995 and July 2012. Serum follicle-stimulating hormone (FSH) level was used as a surrogate marker for ovarian function.
  
  
  RESULTS
  Twenty-one patients were enrolled. The median age and body mass index (BMI) were 31 years (range, 24-39 years) and 21.3 kg/m² (range, 17.7-31.2 kg/m²), respectively. The median serum FSH level after treatment was 7.9 mIU/mL (range, 2.4-143.4 mIU/mL). The median distance from the iliac crest to transposed ovaries on erect plain abdominal x-ray was 0.5 cm (range, -2.7 to 5.2 cm). In multivariate analysis, posttreatment serum FSH levels were significantly associated with the location of transposed ovaries (β = -8.1, P = 0.032), concurrent chemoradiation (CCRT) as an adjuvant therapy (β = 71.08, P = 0.006), and BMI before treatment (underweight: β = -59.93, P = 0.05; overweight: β = -40.62, P = 0.041).
  
  
  CONCLUSIONS
  Location of transposed ovaries, adjuvant CCRT, and BMI before treatment may be associated with ovarian function after treatment. We suggest that ovaries should be transposed as highly as possible during radical hysterectomy to preserve ovarian function in young patients with early cervical cancer who might be a candidate for adjuvant CCRT and who have low BMI before treatment.
authors: Departments of *Obstetrics and Gynecology, and †Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
authors: Aera
authors: A
authors: Yoon
authors: Yoo-Young
authors: YY
authors: Lee
authors: Won
authors: W
authors: Park
authors: Seung Jae
authors: SJ
authors: Huh
authors: Chel Hun
authors: CH
authors: Choi
authors: Tae-Joong
authors: TJ
authors: Kim
authors: Jeong-Won
authors: JW
authors: Lee
authors: Byoung-Gie
authors: BG
authors: Kim
authors: Duk-Soo
authors: DS
authors: Bae
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D000328:Adult; D059925:Anatomic Landmarks; D015992:Body Mass Index; D018288:Carcinoma, Small Cell / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D059248:Chemoradiotherapy; D059186:Chemoradiotherapy, Adjuvant; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D009367:Neoplasm Staging; D010053:Ovary / Q000502:physiology* / Q000601:surgery; D010386:Pelvic Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000601:surgery* / Q000628:therapy; D055815:Young Adult
chemical_list: D005640:Follicle Stimulating Hormone